Resources

Chris Molloy on investment in dementia; AI in healthcare; TechBio; BioJapan; bioProcessUK; Green, Conservative and Labour conferences; and BIA Board elections

The right time to consider transfer pricing and how early stage biotechs can take a more pragmatic approach

Alliance of CGT Manufacturing Partners (ACGMP) founding members aim to help cell and gene therapy developers find manufacturing partners across regions and modalities, with a shared focus on global patient access.

ELRIG announced the keynote speakers for Protein Sciences in Drug Discovery 2026.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

 What future-proofing means in regulated scientific environments

Coulter Partners successfully led a search assignment for Valo Therapeutics Group to place Carlos de Sousa, M.D., MBA, as Chief Executive Officer.

Poolbeg Pharma announces that a South Korean patent relating to POLB 001 has been formally granted.

Cancer Research UK have signed an agreement with ORIC Pharmaceuticals, Inc. to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.

Chris Molloy on the Labour Party conference; female biotech leaders in Edinburgh; Women in Biotech mentoring programme; Advanced Therapy Treatment Centre; BioSolutions Advisory Board; TechBio UK; and careers at BIA

Thoughtful digitalisation discussions at the premier meeting of women in biotech in Scotland

Aravax announces it will be communicating topline results from its Phase 2 study of its lead product, PVX108 for the treatment of peanut allergy, at major conferences in the US and Europe in November 2026

The Cell and Gene Therapy (CGT) Catapult has published new insights into the advancement of the UK’s cell and gene therapy industry in its Annual Review.

Brainomix announced new data published in the esteemed American Journal of Respiratory & Critical Care Medicine (AJRCCM)

Medicines Discovery Catapult has appointed Dr Mike Strange as its Chief Executive Officer.

Poolbeg Pharma announces its unaudited interim results for the six months to 30 June 2026.

Poolbeg Pharma reaffirmed that participant recruitment for the POLB 001 TOPICAL trial is progressing well. Following the previously announced six-patient safety cohort, a total of eight participants have now been dosed out of c.30, since the first patient dosed in July 2026.

Global drug development consultancy Boyds has strengthened its Regulatory Affairs team with the appointment of two senior specialists.